跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ACTRN12623001042639
ACTRN12623001042639招募中1 期

Efficacy of Low Dose Naltrexone for the treatment of symptoms of Post COVID-19 Condition

Griffith University0 个研究点目标入组 56 人开始时间: 2023年9月26日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
56
研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 65 Years（—）
性别
All

入选标准

  • •Participants with long COVID according to the World Health Organization working case definition (Individuals with a history of probable or confirmed SARS-CoV-2 (COVID-19) three months from COVID-19 onset with symptoms lasting at least two months).
  • •Present with symptoms including cognitive disturbances (brain fog), sleep disturbances, and/or body pain.

排除标准

  • •i.Current respiratory infections
  • •ii.Intercurrent SARS-CoV-2 reinfection during trial period (this will be considered drop-out)
  • •iii.Previous clinical diagnosis of ME/CFS
  • •iv.Chronic pain history prior to long COVID onset
  • •v.Adverse reaction to LDN or compounded constituents
  • •vi.Chronic opioid or substitution therapy
  • •vii.Daily opioid use in three months prior to, or during trial
  • •viii.Substance abuse, dependence, addiction
  • •ix.History of drug, alcohol abuse and recreational drugs
  • •x.Pregnancy or breastfeeding
  • •xi.Renal dysfunction (eGFR greater than 30 ml/min/1.73m2), liver dysfunction (ALT or AST greater than 300 IU/L).
  • •xii.Active cancer.
  • •xiii.Inflammatory (rheumatological, GIT, dermatological) or neurological condition (demyelinating).
  • •xiv.Neuroimmune modulators: DMARDs, steroids, minocycline, metformin.
  • •xv.History of anxiety, depression and/or other psychiatric concerns.
  • •xvi.Language, cognition, no computer literacy.

研究者

相似试验

进行中（未招募）
1 期
To evaluate the effect of low-dose naltrexone (LDN) on pain perception and quality of life in wome
EUCTR2022-000245-33-PLMedical University of Lublin300
尚未招募
3 期
Evaluation of the effect of low-dose naltrexone in patients with Trigeminal Neuralgia and Chronic migraine patientsTrigeminal neuralgiaCondition 1: Trigeminal Neuralgia. Condition 2: Chronic Migraine.Chronic migraine without auraG50.0G43.7
IRCT20171109037332N2Kerman University of Medical Sciences40
已完成
3 期
Efficacy of low-dose naloxone for the prevention of acute remifentanil-induced hyperalgesia
IRCT20101122005225N8Tehran University of Medical Sciences75
进行中（未招募）
1 期
A preliminary study of Low Dose Naltrexone for the induction of remission in patients with mild to moderate Crohn’s Disease that failed conventional treatment: The LDN Crohn study.
EUCTR2019-000852-32-NLErasmusMC122
招募中
不适用
ow Dose Naltrexone for the induction of remission in patients with mild to moderate Crohn’s Diseasethat failed conventional treatment
NL-OMON21939ZonMW122